Figure 1

Cumulative incidence rates for CNS progression, non-CNS progression, and death in alectinib-treated patients in the pivotal phase II studies. (A) The overall pooled population, (B) patients with baseline CNS metastases, and (C) patients without baseline CNS metastases. CNS=central nervous system; PD=progressive disease.